

RECEIVED  
CENTRAL FAX CENTER

JUN 12 2006

HUBR 1261-US (10404743)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) Hofgen, et al.  
Serial No. 10/826,136  
Filed April 16, 2004  
For 7-AZAINDOLES AND THE USE THEREOF AS  
THERAPEUTIC AGENTS  
Art Unit 1625  
Examiner R. J. Ballis

June 12, 2006

This is to certify that this correspondence is being sent by facsimile to 1-571-273-8300 addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Va. 22313-1450 on the date shown below

*Eileen Sheffield*  
Eileen Sheffield Date 6/12/06

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Va. 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an

25665180.1

1


admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0624, under Order No. NY-HUBR-1261-US. A duplicate copy of this paper is enclosed.

Respectfully submitted

FULBRIGHT & JAWORSKI L.L.P.

By   
James R. Crawford  
Reg. No: 39,155

666 Fifth Avenue  
New York, New York 10103  
(212) 318-3148  
Enclosures

RECEIVED  
CENTRAL FAX CENTER

**JUN 12 2006**

PTQ/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/826,136
				Filing Date	April 16, 2004
				First Named Inventor	Hofgen, et al.
				Art Unit	1625
				Examiner Name	R. J. Balls
				Attorney Docket Number	NY-HUBR 1261-US
Sheet	1	of	1		

[illegible][illegible]

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinda Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
	CA	Hulme, et al. "Orally Active Indole N-Oxide PDE4 Inhibitors", Bioorganic and Medicinal Chemistry Letters (1998), 8, 3053-3058)		
Examiner Initials	Cite			T <sup>2</sup>
Examiner Signature			Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

25153840